Bing

SEARCH HISTORY

Roth Capital reaffirmed their buy rating on shares of Rexahn Pharmaceuticals (NYSE:RNN) in a report released on Wednesday. Roth Capital currently has a $3.00 price objective on the stock. Roth Capital has also updated their ratings on a number of other ...
Mideast Times · 5/15/2015
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 6.2% to $0.76 on 3.3x average daily volume. Rexahn Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 514,000 shares per day. The …
Financial News Network Online · ByMallory Stone · 5/21/2015
They set a “buy” rating and a $1.25 price target on the stock. Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.7023 on Wednesday. Rexahn Pharmaceuticals has a 1-year low of $0.6500 and a 1-year high of $1.0500. The stock has a 50-day …
sleekmoney.com · 5/13/2015
More from Bing News
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> REXAHN PHARMACEUTICALS INC (RNN): Free Stock Analysis Report ACTELION LTD …
Yahoo Finance · 1/27/2014
Rexhan Pharmaceuticle Inc (NYSEMKT:RNN)’s stock price surged by 62.86% in Friday’s trading session. Apparently, the decision to stay focused solely on oncology Niche was the biggest catalyst for this rise. There is great prospect for this …
Live Trading News · 1/11/2014
Rexahn’s three clinical stage drug candidates are Archexin, Serdaxin, and Zoraxel. With RNN stock up +78% since the start of the year, shareholders may wan to keep their eye on this stock and its positive track record for beating EPS estimates.
Investor Place · 8/30/2010
Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating ...
StreetInsider · 12/11/2013
Rexahn Pharmaceuticals, Inc. ( RNN) was a big mover last session, as its shares rose almost 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company …
NASDAQ · 9/5/2014
Take all of it with a grain of salt. Ironically, the only thing you want to worry about right new isn't the news itself, but rather, a chart of RNN since the chart of this stock illustrates the ever-changing opinion of the stock and the constantly-changing ...
Smallcap Network · ByJames E. Brumley · 10/14/2013
They set a “buy” rating and a $1.25 price target on the stock. Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.7152 on Tuesday. Rexahn Pharmaceuticals has a 1-year low of $0.6500 and a 1-year high of $1.0500. The stock has a 50-day moving …
Ticker Report · 4/28/2015